US2006024300A1PendingUtilityA1

Immunoglobulin variants and uses thereof

59
Assignee: GENENTECH INCPriority: Dec 16, 2002Filed: Jul 26, 2005Published: Feb 2, 2006
Est. expiryDec 16, 2022(expired)· nominal 20-yr term from priority
Inventors:Camellia W. AdamsAndrew ChanCraig CrowleyHenry B. LowmanGerald R. NakamuraLeonard G. Presta
A61P 9/08A61P 9/00A61P 35/00A61P 9/10A61P 37/02A61P 5/40A61P 5/14A61P 37/06A61P 7/06A61P 5/00A61P 37/08A61P 3/10A61P 7/04A61P 37/00A61P 35/02A61P 31/18A61P 9/14A61P 43/00A61P 31/06A61P 27/02A61P 29/00A61P 25/00A61P 27/16A61P 11/06A61P 11/00A61P 21/04A61P 15/08A61P 19/02A61P 17/14A61P 1/16A61P 13/12A61P 11/08A61P 11/02A61P 1/12A61P 17/02A61P 17/00A61P 1/04A61P 1/00A61P 17/06C07K 2317/56C07K 2317/24C07K 2317/734C07K 2317/75C07K 2317/52C07K 2317/732C07K 2317/41C07K 16/2887C07K 2317/92C12N 15/63C12N 5/16A61K 2039/505C07K 2317/72C07K 2317/565C07K 2317/73C07K 2317/55C07K 2317/522A61K 39/39558C07K 2317/567C07K 16/00C07K 16/28
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Claims

exact text as granted — not AI-modified
1 . A variant of humanized antibody 2H7.v16 that binds human CD20, or an antigen-binding fragment thereof, wherein the variant antibody exhibits at least four fold higher antibody dependent cellular cytotoxicity (ADCC) activity than antibody 2H7.v16.  
     
     
         2 . The variant antibody of  claim 1  wherein the antibody comprises a human IgG1 Fc region.  
     
     
         3 . The variant antibody of  claim 2  wherein the antibody is 2H7.v114  
     
     
         4 . The variant antibody of  claim 2  wherein the antibody exhibits at least ten fold higher antibody dependent cellular cytotoxicity (ADCC) activity than antibody 2H7.v16  
     
     
         5 . The variant antibody of  claim 4  wherein the antibody is 2H7.v138.  
     
     
         6 . A variant of humanized antibody 2H7.v16 that binds human CD20, or an antigen-binding fragment thereof, wherein the variant antibody exhibits at least 7.5 fold improved complement dependent cytotoxicity (CDC) than antibody 2H7.v16.  
     
     
         7 . The variant antibody of  claim 6  wherein the antibody is 2H7.v114  
     
     
         8 . The variant antibody of  claim 6  wherein the antibody exhibits at least 25 fold improved complement dependent cytotoxicity (CDC) than antibody 2H7.v16.  
     
     
         9 . The variant antibody of  claim 8 , wherein the antibody is 2H7.v138.  
     
     
         10 . The variant antibody of  claim 6  wherein the antibody further exhibits at least 4 fold higher antibody dependent cellular cytotoxicity (ADCC) activity than antibody 2H7.v16.  
     
     
         11 . The variant antibody of  claim 6 , wherein the antibody further exhibits at least 10 fold higher antibody dependent cellular cytotoxicity (ADCC) activity than antibody 2H7.v16.  
     
     
         12 . A method of depleting human B cells in vivo comprising administering to a subject, the antibody of  claim 3 .  
     
     
         13 . A method of depleting B cells in vivo comprising administering to a subject the antibody of  claim 5.

Join the waitlist — get patent alerts

Track US2006024300A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.